Skip to content
Menu

Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.

Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.

Read at benzinga.com

← All stock news